Plus Therapeutics is pleased to announce that the first patients have been treated in the ReSPECT-LM dose optimization clinical trial, evaluating REYOBIQ™ (rhenium Re 186 obisbemeda) for the treatment of leptomeningeal metastases (LM)—a devastating and often under-treated complication of metastatic cancer.
This Phase 1/2 clinical trial builds on the success of Plus Therapeutics’ completed Phase 1 single-dose escalation study, which demonstrated the feasibility, safety, and early efficacy potential of REYOBIQ™ in patients with LM. The new study is focused on identifying the optimal dosing regimen to inform a future registrational trial.
The trial has been carefully designed in alignment with the FDA’s Project Optimus initiative, which emphasizes dose optimization in oncology drug development to enhance both efficacy and safety.
“The rapid enrollment of initial patients and the design alignment with FDA’s Project Optimus demonstrate our commitment to delivering targeted, data-driven therapies to patients who urgently need better options,” said Dr. Andrew Brenner, Principal Investigator and neuro-oncologist at UT Health San Antonio.
The ReSPECT-LM trial is supported by a $17.6 million non-dilutive funding award from the Cancer Prevention and Research Institute of Texas (CPRIT) and represents a significant step forward in addressing an area of high unmet medical need, particularly among patients with metastatic breast and lung cancer.
Read the full press release:
Plus Therapeutics Announces Initial Patients Treated in ReSPECT-LM Trial
Explore detailed trial information, eligibility criteria, and locations:
Learn more about ReSPECT-LM at respect-trials.com
#PlusTherapeutics #PSTV #ReSPECTLM #REYOBIQ #LeptomeningealMetastases #BrainCancer #ClinicalTrials #CancerResearch #ProjectOptimus #Radiotherapeutics #NeuroOncology #MetastaticCancer #BreastCancer #LungCancer
Recent Comments